{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:14:21Z","timestamp":1783379661388,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128405","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:52:45Z","timestamp":1772596365000},"page":"128405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England"],"prefix":"10.1016","volume":"78","author":[{"given":"Chu-Chang","family":"Ku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rosello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen B.","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Baguelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2026.128405_bb0005","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/bjd.16399","article-title":"Inequalities in zoster disease burden: a population-based cohort study to identify social determinants using linked data from the U.K. clinical practice research datalink","volume":"178","author":"Jain","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128405_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128405_bb0015","first-page":"475","article-title":"Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged \u226550 years: a prospective study","volume":"76","author":"Schmidt-Ott","year":"2018","journal-title":"J Inf Secur"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128405_bb0020","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.vaccine.2018.02.021","article-title":"Effectiveness of herpes zoster vaccination in an older United Kingdom population","volume":"36","author":"Walker","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128405_bb0025","author":"UK Health Security Agency"},{"key":"10.1016\/j.vaccine.2026.128405_bb0030","author":"Shingrix | European Medicines Agency (EMA)"},{"key":"10.1016\/j.vaccine.2026.128405_bb0035","series-title":"Cost-Effectiveness of the Herpes Zoster Subunit (Shingrix, HZ\/Su) and Live Attenuated (Zostavax, ZVL) Vaccines. Report for the JCVI Varicella\/Zoster Sub-Committee, 23\/03\/2018","article-title":"BMJM","author":"Rosello","year":"2018"},{"key":"10.1016\/j.vaccine.2026.128405_bb0040","series-title":"Shingles (herpes zoster): immunisation against infectious disease","author":"UK Health Security Agency","year":"2021"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128405_bb0045","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128405_bb0050","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"Van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128405_bb0055","doi-asserted-by":"crossref","unstructured":"Ku CC, Rosello A, Hobbelen P, et al. Health-related quality of life with herpes zoster: systematic review and analysis of individual patient data from 9 cohorts. medRxiv. Published online April 29, 2025:2025.04.28.25326561. doi:https:\/\/doi.org\/10.1101\/2025.04.28.25326561.","DOI":"10.1101\/2025.04.28.25326561"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128405_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyx015","article-title":"Data resource profile: hospital episode statistics admitted patient care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128405_bb0065","doi-asserted-by":"crossref","DOI":"10.7551\/mitpress\/3206.003.0014","article-title":"Gaussian processes for machine learning","author":"Rasmussen","year":"2005","journal-title":"Gaussian Process Mach Learn"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128405_bb0070","first-page":"241","article-title":"The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013","volume":"73","author":"Hobbelen","year":"2016","journal-title":"J Inf Secur"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128405_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jval.2022.07.005","article-title":"Quality-adjusted life expectancy norms for the English population","volume":"26","author":"McNamara","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128405_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2026.128405_bb0085","author":"Office for National Statistics"},{"key":"10.1016\/j.vaccine.2026.128405_bb0090","author":"Office for National Statistics"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128405_bb0095","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1016\/j.vaccine.2019.07.004","article-title":"Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention","volume":"37","author":"Klein","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128405_bb0100","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","article-title":"Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis","volume":"3","author":"Mbinta","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.vaccine.2026.128405_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103241","article-title":"Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications","volume":"83","author":"Strezova","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2026.128405_bb0110","series-title":"JCVI Code of Practice","author":"Joint Committee on Vaccination and Immunisation","year":"2013"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128405_bb0115","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.jval.2022.09.863","article-title":"Public health impact of introducing Adjuvanted recombinant zoster vaccine into the vaccination Programme in the UK","volume":"25","author":"Hunjan","year":"2022","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128405_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128405_bb0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40258-019-00491-6","article-title":"Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults","volume":"17","author":"McGirr","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"33","key":"10.1016\/j.vaccine.2026.128405_bb0130","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"issue":"49","key":"10.1016\/j.vaccine.2026.128405_bb0135","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"issue":"8062","key":"10.1016\/j.vaccine.2026.128405_bb0140","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-025-08800-x","article-title":"A natural experiment on the effect of herpes zoster vaccination on dementia","volume":"641","author":"Eyting","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128405_bb0145","article-title":"Reduced dementia incidence after varicella zoster vaccination in Wales 2013\u20132020","volume":"8","author":"Schnier","year":"2022","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128405_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020528","article-title":"Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the clinical practice research datalink 2000-2012","volume":"8","author":"Yanni","year":"2018","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128405_bb0155","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","article-title":"Quantification of risk factors for postherpetic neuralgia in herpes zoster patients","volume":"87","author":"Forbes","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128405_bb0160","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2168952","article-title":"Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: an updated critical review","volume":"19","author":"Giannelos","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128405_bb0165","author":"UK Health Security Agency"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128405_bb0170","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Crombie","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.vaccine.2026.128405_bb0175","article-title":"Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data","volume":"368","author":"Forbes","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128405_bb0180","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.vaccine.2021.01.061","article-title":"Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: a systematic review","volume":"39","author":"Hodgkinson","year":"2021","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:26:14Z","timestamp":1783376774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"alternative-id":["S0264410X26002136"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128405","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128405"}}